Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cuasay, Katrina
ALTITUDE-AD, NCT06335173: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease	Active, not recruiting	2	540	Europe, Canada, US	sabirnetug, Placebo	Acumen Pharmaceuticals	Alzheimer Disease	10/26	10/26
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies	Completed	2	130	US	CT1812	Cognition Therapeutics, National Institute on Aging (NIA)	Dementia With Lewy Bodies	11/24	11/24
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)	Recruiting	2	220	Europe, US	FNP-223, Placebo	Ferrer Internacional S.A.	Progressive Supranuclear Palsy	11/26	11/26
EIP21-NFD-504, NCT05869669: RewinD-LB - Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies	Active, not recruiting	2	159	Europe, US	Neflamapimod, VX-745, Placebo	EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc	Dementia with Lewy Bodies	10/24	06/25
Besselaar
ALTITUDE-AD, NCT06335173: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease	Active, not recruiting	2	540	Europe, Canada, US	sabirnetug, Placebo	Acumen Pharmaceuticals	Alzheimer Disease	10/26	10/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cuasay, Katrina
ALTITUDE-AD, NCT06335173: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease	Active, not recruiting	2	540	Europe, Canada, US	sabirnetug, Placebo	Acumen Pharmaceuticals	Alzheimer Disease	10/26	10/26
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies	Completed	2	130	US	CT1812	Cognition Therapeutics, National Institute on Aging (NIA)	Dementia With Lewy Bodies	11/24	11/24
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)	Recruiting	2	220	Europe, US	FNP-223, Placebo	Ferrer Internacional S.A.	Progressive Supranuclear Palsy	11/26	11/26
EIP21-NFD-504, NCT05869669: RewinD-LB - Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies	Active, not recruiting	2	159	Europe, US	Neflamapimod, VX-745, Placebo	EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc	Dementia with Lewy Bodies	10/24	06/25
Besselaar
ALTITUDE-AD, NCT06335173: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease	Active, not recruiting	2	540	Europe, Canada, US	sabirnetug, Placebo	Acumen Pharmaceuticals	Alzheimer Disease	10/26	10/26